

NATIONAL CANCER INSTITUTE AT FREDERICK (NCI@F)
INSTITUTIONAL BIOSAFETY COMMITTEE
MINUTES
FEBRUARY 18, 2014

CALL TO ORDER / ANNOUNCEMENTS

The NCI@F Institutional Biosafety Committee was convened at 12:04 pm in Building 549 Executive Board Room with the following members in attendance:

Voting (Quorum = 8)

- | | |
|--|---|
| <input type="checkbox"/> Katalin Baranji (regrets) | <input checked="" type="checkbox"/> Stephen Hughes |
| <input type="checkbox"/> Michael Baseler (regrets) | <input checked="" type="checkbox"/> Sarah Hooper |
| <input checked="" type="checkbox"/> Theresa Bell | <input type="checkbox"/> Serguei Kozlov (regrets) |
| <input checked="" type="checkbox"/> Rev. David Betzner | <input checked="" type="checkbox"/> Dan McVicar (Chair) |
| <input checked="" type="checkbox"/> Stephen Creekmore | <input checked="" type="checkbox"/> Raja Sriperumbudur |
| <input checked="" type="checkbox"/> Bruce Crise | <input type="checkbox"/> Lucien Winegar (regrets) |
| <input checked="" type="checkbox"/> Eric Freed | <input type="checkbox"/> Enrique Zudaire (regrets) |
| <input checked="" type="checkbox"/> Melinda Hollingshead | |

Non-Voting

- Walter Hubert
- Karen Barber
- Terri Bray

APPROVAL OF MINUTES FROM DECEMBER 17, 2013 MEETING

The minutes from the December 17, 2013 meeting were approved as written. A motion and second were made (For: 10; Against: 0; Abstain: 0)

ACCIDENT REVIEWS - Sterile needle stick when removing cap from package. A few clarifications requested by committee members: Why do you use needles instead of pipettes?

REVIEW OF PROTOCOLS

NEW REGISTRATIONS

Zhi-Ming (Thomas) Zheng – 14-04: Tumor Virus RNA Biology. The is a study of tumor viruses including human papillomavirus and Kaposi sarcoma-associated herpes virus in attempt to understand how these tumor viruses infection lead to the development of cancer. Deferred to full committee pending clarifications: For: 10; Against: 0; Abstain: 0

Paul Roche – 14-07 – Expression of mutant MHC class II molecules in BM cells for transplantation to assess immune competence. The goal of this project is to identify the importance of the cytoplasmic tail and transmembrane domains of the MHC class II beta chain in the function of MHC class II molecules in antigen presenting cells. The committee moved to conditional approval pending clarifications. For: 10; Against: 0; Abstain: 0

NATIONAL CANCER INSTITUTE AT FREDERICK (NCI@F)
INSTITUTIONAL BIOSAFETY COMMITTEE
MINUTES
DECEMBER 17, 2013

Nataschia Marino – 14-08 – Metastasis suppression function of NM23-H1 in an animal model breast cancer. The use of the murine mammary carcinoma cell line, 4T1-luc2, to create a spontaneous metastatic model. Approved: For: 10; Against: 0; Abstain: 0

RENEWALS

Yinling Hu – 14-01 (09-12) – Role of Ikk α in Cancer and Inflammation. The importance for the development of squamous cell carcinomas in human and mice and for inflammation and immune function. The committee moved to conditional approval pending clarifications. For: 10; Against: 0; Abstain: 0

Larry Anderson – 14-02 (09-45) – clinical and Pre-clinical pharmacology analytical methods. To develop and use methods of analysis to gather information on the disposition and actions of potential new anti-tumor agents in biological systems. Deferred to full committee pending clarifications: For: 10; Against: 0; Abstain: 0

Terry Van Dyke – 14-03 (10-47) – Investigation of the molecular mechanisms of tumorigenesis using inducible genetically engineered mouse models (GEMMs). This project uses genetically engineered mouse models to study the molecular mechanisms of tumorigenesis. The committee moved to conditional approval pending clarifications. For: 10; Against: 0; Abstain: 0

Lionel Feigenbaum – 14-05 (10-52) – Production of Genetically Engineered Mice. To generate genetically engineered mice for the NIH scientific community. The committee moved to conditional approval pending clarifications. For: 10; Against: 0; Abstain: 0

John Gilly 14-06 (10-16) – Use of HEK 293 cells for alphavirus vaccine production.

OUTSTANDING ITEMS

Dimitar Dimitrov 13-38 (04-04, 08-20): Developing anti-viral vaccines and human antibodies against infectious diseases and cancer antigens by using recombinant membrane proteins of HIV, Nipah, Hendra, Dengue viruses and cancer antigens. Committee requested additional clarifications and a Vaccinia-specific SOP as well as a lab visit. Post-meeting, Theresa Bell learned that the lab was relocating and suggested that the space that will be used for the Vaccinia work should not be evaluated until the move has been completed. No Vaccinia work is being performed at this time. **Continue deferral until lab move and observation is completed.** For: 8; Against: 0; Abstain: 0

George Pavlakis – 13-80 (New): Use of Lymphodepletion and Adoptive Cell Transfer in the Evaluation of Cancer Vaccine in Mouse Models. This registration is for the use of recombinant vaccinia virus as a vaccine vector against melanoma using the mouse model. Two representatives from the lab were present to discuss the IBC concerns. There were questions during the pre-review. The committee requested that the PI provide a section B for recombinant work and a lab specific SOP that addresses Vaccinia. This registration was deferred to full committee after clarification and documentation are submitted. For: 8; Against: 0; Abstain: 0

AMENDMENTS

Twenty six amendments were processed and approved between the December and January IBC meetings.

OTHER BUSINESS

NATIONAL CANCER INSTITUTE AT FREDERICK (NCI@F)
INSTITUTIONAL BIOSAFETY COMMITTEE
MINUTES
DECEMBER 17, 2013

IBC webpage registration update: Online IBC web registration update – DMS to provide training on the new registration program. Training to be scheduled this month.

ADJOURNMENT

The meeting adjourned at 1:55 pm.

Next meetings:

March 18, 2014

April 15, 2014